Influence of cancer medications on COVID-19
2024
University of Zagreb, Zagreb, Croatia
People with lymphoid malignancies (such as lymphomas) have an increased risk of dying from COVID-19 or remaining infected for an extended period. This retrospective study examines the impact of different cancer therapies on the course of infection. An analysis of 314 patients with lymphoid malignancies who contracted COVID-19 between October 2020 and April 2021 revealed significant differences depending on treatment status. In the group of patients currently undergoing treatment, the mortality rate was significantly higher (35%) compared to patients who had completed therapy (15%).
The results show that age and certain medications (such as purine analogues) are key factors that increase the risk of a severe or prolonged course of COVID-19 in patients with lymphoid malignancies.
Treatment-related risk factors for adverse outcomes of COVID-19 in patients treated for lymphoid malignancies in the pre-omicron era—A study of KroHem, the Croatian group for hematologic diseases
Igor Aurer
Added on: 05-15-2025
[1] https://www.mdpi.com/2227-9059/12/2/331
